Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -2.7% Market Closed
Market Cap: 190.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Arovella Therapeutics Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Arovella Therapeutics Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Arovella Therapeutics Ltd
ASX:ALA
Cash from Operating Activities
-AU$6.9m
CAGR 3-Years
-25%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash from Operating Activities
-AU$15.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash from Operating Activities
AU$119.5m
CAGR 3-Years
N/A
CAGR 5-Years
117%
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash from Operating Activities
-AU$8.1m
CAGR 3-Years
-40%
CAGR 5-Years
9%
CAGR 10-Years
-20%
Probiotec Ltd
ASX:PBP
Cash from Operating Activities
AU$15.7m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
9%
Vita Life Sciences Ltd
ASX:VLS
Cash from Operating Activities
AU$11.1m
CAGR 3-Years
17%
CAGR 5-Years
39%
CAGR 10-Years
8%
No Stocks Found

Arovella Therapeutics Ltd
Glance View

Market Cap
189.1m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
0.01 AUD
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Arovella Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-6.9m AUD

Based on the financial report for Jun 30, 2024, Arovella Therapeutics Ltd's Cash from Operating Activities amounts to -6.9m AUD.

What is Arovella Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-23%

Over the last year, the Cash from Operating Activities growth was -8%. The average annual Cash from Operating Activities growth rates for Arovella Therapeutics Ltd have been -25% over the past three years , -23% over the past five years .

Back to Top